Status:
TERMINATED
TDCS and Aphasia Therapy in the Chronic Phase After Stroke
Lead Sponsor:
University Hospital, Ghent
Conditions:
Aphasia Following Cerebral Infarction
Aphasia Following Nontraumatic Intracerebral Hemorrhage
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
This study evaluates the neuromodulatory effect of combined tDCS and aphasia therapy in patients in the chronic phase after stroke. Half of the participants will receive aphasia therapy and tDCS, the ...
Detailed Description
Aphasia is present in about one third of all stroke patients in the chronic phase. The first few months after stroke, considerable spontaneous recovery is initiated, including neuronal plasticity and ...
Eligibility Criteria
Inclusion
- Diagnosed with mild to moderate aphasia (Token Test Score between 7 and 40) after a first left hemispheric ischemic or hemorrhagic stroke
- Inclusion \> 6 months post-stroke
- Age 18 - 85 years
- Being right-handed (\> +8 on the questionnaire for handedness, Van Strien)
- Mothertongue: Dutch
- Imaging (CT or MRI) prior to inclusion (in patient file), standard of care in the acute phase
- Signed Informed Consent (attachment 1)
Exclusion
- History of other diseases of the central nervous system, psychological disorders and (developmental) speech and or language disorders
- Serious non-linguistic, cognitive disorders (as documented in the patients' medical history and inquired in the anamneses)
- Prior brain surgery
- Excessive use of alcohol or drugs
- New neurological symptoms between the acute stage and inclusion
Key Trial Info
Start Date :
November 24 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 18 2018
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03305614
Start Date
November 24 2017
End Date
April 18 2018
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ghent
Ghent, East-Flanders, Belgium, 9000